No, Florinef (fludrocortisone) causes hypokalemia, not hyperkalemia
Fludrocortisone is a mineralocorticoid that promotes potassium excretion and causes hypokalemia (low potassium), not hyperkalemia. This is its primary mechanism of action and a well-established adverse effect.
Mechanism of Action
Fludrocortisone acts directly on the renal distal tubules to promote sodium retention and potassium excretion 1, 2. This mineralocorticoid effect is the opposite of what would cause hyperkalemia—it actively lowers potassium levels.
Evidence from FDA Drug Label
The FDA-approved drug label for Florinef explicitly lists hypokalemia (low potassium) as an adverse reaction, not hyperkalemia 3. The label states:
- Most adverse reactions include "potassium loss and hypokalemic alkalosis" 3
- Overdosage signs include "hypokalemia, excessive increase in weight, and increase in heart size" 3
- "Muscular weakness may develop due to excessive potassium loss" requiring potassium supplementation 3
Clinical Use for Hyperkalemia Treatment
Paradoxically, fludrocortisone is actually used to treat hyperkalemia, not cause it:
- Multiple studies demonstrate fludrocortisone effectively lowers elevated potassium levels in various clinical scenarios 4, 5, 6, 7, 8, 9
- In CKD patients with hyperkalemia, fludrocortisone (0.05-0.1 mg/day) reduced serum potassium from 6.14 mEq/L to 4.52 mEq/L 5
- In renal transplant recipients with calcineurin inhibitor-induced hyperkalemia, fludrocortisone significantly improved potassium levels (5.18 to 4.4 mmol/L) 6
Important Clinical Caveat: Hypokalemia Risk
The primary electrolyte concern with fludrocortisone is hypokalemia requiring potassium supplementation, particularly in:
- Patients with subarachnoid hemorrhage receiving fludrocortisone for hyponatremia—hypokalemia was the main side effect requiring potassium supplementation 10
- Patients on chronic therapy who require regular electrolyte monitoring 11, 12
- Elderly patients who may develop severe symptomatic hypokalemia requiring drug discontinuation 13
Monitoring Requirements
When prescribing fludrocortisone 1, 11:
- Monitor serum potassium levels regularly—expect them to decrease
- Watch for signs of hypokalemia: muscle weakness, cramping, cardiac arrhythmias
- Provide potassium supplementation as needed
- Patients should avoid potassium-containing salt substitutes as they interfere with the sodium-retaining effects 1